Somatic activation of oncogenic Kras in hematopoietic cells initiates a rapidly fatal myeloproliferative disorder
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
RAS mutations are common in myeloid malignancies; however, it is not known whether oncogenic RAS can initiate leukemia. We show that expressing mutant K-Ras(G12D) protein from the endogenous murine locus rapidly induces a fatal myeloproliferative disorder with 100% penetrance characterized by tissue infiltration, hypersensitivity to growth factors, and hyperproliferation. Hematopoietic cells from diseased mice demonstrated increased levels of Ras-GTP, but effector kinases were not constitutively phosphorylated and responded normally to growth factors. Oncogenic RAS is sufficient to initiate myeloid leukemogenesis in mice, and this provides an in vivo system for biologic and preclinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Expression of the most common KRAS mutation (G12D) in mouse hematopoietic cells causes a fatal myeloproliferative neoplasm (MPN).6,7”
From USP22 deficiency leads to myeloid leukemia upon oncogenic Kras activation through a PU.1-dependent mechanism (2018) · cites this paper as [6]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a
Serrano, M., Lin, A. W., McCurrach, M. E., Beach, D., & Lowe, S. W. (1997) · Cell · doi:10.1016/s0092-8674(00)81902-9 · Cited by 5,218
ras oncogenes in human cancer: a review.
Bos, J. L. (1989) · PubMed · Cited by 5,061
The GTPase superfamily: conserved structure and molecular mechanism
Bourne, H. R., Sanders, D. A., & McCormick, F. (1991) · Nature · doi:10.1038/349117a0 · Cited by 3,392
Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification
Gorre, M. E., Mohammed, M., Ellwood, K., Hsu, N., Paquette, R., Rao, P. N., & Sawyers, C. L. (2001) · Science · doi:10.1126/science.1062538 · Cited by 3,104
The GTPase superfamily: a conserved switch for diverse cell functions
Bourne, H. R., Sanders, D. A., & McCormick, F. (1990) · Nature · doi:10.1038/348125a0 · Cited by 2,333
Proteins regulating Ras and its relatives
Boguski, M. S., & McCormick, F. (1993) · Nature · doi:10.1038/366643a0 · Cited by 1,901
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras
Jackson, E. L., Willis, N., Mercer, K., Bronson, R. T., Crowley, D., Montoya, R., Jacks, T., & Tuveson, D. A. (2001) · Genes & Development · doi:10.1101/gad.943001 · Cited by 1,898
Self-citationThiede, C., Steudel, C., Mohr, B., Schaich, M., Schäkel, U., Platzbecker, U., Wermke, M., Bornhäuser, M., Ritter, M., Neubauer, A., et al. (2002) · Blood · doi:10.1182/blood.v99.12.4326 · Cited by 1,735
Mutations in PTPN11, encoding the protein tyrosine phosphatase SHP-2, cause Noonan syndrome
Tartaglia, M., Mehler, E. L., Goldberg, R., Zampino, G., Brunner, H. G., Kremer, H., van der Burgt, I., Crosby, A. H., Ion, A., Jeffery, S., et al. (2001) · Nature Genetics · doi:10.1038/ng772 · Cited by 1,733
Inducible Gene Targeting in Mice
Kühn, R., Schwenk, F., Aguet, M., & Rajewsky, K. (1995) · Science · doi:10.1126/science.7660125 · Cited by 1,641
Research works printed but not linked: 6
- Bos, J. L. (1989) Cancer Res. 49, 4682-4689.
- Padua, R. A., Carter, G., Hughes, D., Gow, J., Farr, C., Oscier, D., McCormick, F. & Jacobs, A. (1988) Leukemia 2, 503-510.
- Bashey, A., Gill, R., Levi, S., Farr, C. J., Clutterbuck, R., Millar, J. L., Pragnell, I. B. & Marshall, C. J. (1992) Blood 79, 981-989. · doi:10.1182/blood.v79.4.981.bloodjournal794981
- Dunbar, C. E., Crosier, P. S. & Nienhuis, A. W. (1991) Oncogene Res. 6, 39-51.
- Hawley, R. G., Lieu, F. H., Fong, A. Z. & Hawley, T. S. (1994) Gene Ther. 1, 136-138.
- Donovan, S., Shannon, K. M. & Bollag, G. (2002) BBA Rev. Cancer. 1602, 23-45.
Cited by
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789
Hyperactive Ras in developmental disorders and cancer
Schubbert, S., Shannon, K., & Bollag, G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2109 · Cited by 1,583
Self-citationMechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia
Ren, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1567 · Cited by 878
“DH p185 (1-426) p210 (1-902–927) p230 (1–1,176) Y177 Myr GAG BCR F G 1a 1b”
Tuveson, D. A., Shaw, A. T., Willis, N. A., Silver, D. P., Jackson, E. L., Chang, S., Mercer, K. L., Grochow, R., Hock, H., Crowley, D., et al. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00085-6 · Cited by 798
Self-citationASXL1 Mutations Promote Myeloid Transformation through Loss of PRC2-Mediated Gene Repression
Abdel-Wahab, O., Adli, M., LaFave, L. M., Gao, J., Hricik, T., Shih, A. H., Pandey, S., Patel, J. P., Chung, Y. R., Koche, R., et al. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.06.032 · Cited by 599
Araki, T., Mohi, M. G., Ismat, F. A., Bronson, R. T., Williams, I. R., Kutok, J. L., Yang, W., Pao, L. I., Gilliland, D. G., Epstein, J. A., et al. (2004) · Nature Medicine · doi:10.1038/nm1084 · Cited by 420
“or mice with activated K-ras expressed selectively in hematopoietic progenitor”
BackgroundMullally, A., Lane, S. W., Ball, B., Megerdichian, C., Okabe, R., Al-Shahrour, F., Paktinat, M., Haydu, J. E., Housman, E., Lord, A. M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.015 · Cited by 395
“The Jak2V617F MPN-Initiating Population Is Contained within the HSC-Enriched LSK Population Existing murine MPN models have generally demonstrated poor transplantability of the primary disease (Chan et al., 2004, 2009; Braun et al., 2004; Lee et al., 2007), limiting the evaluation of the disease-initiating population…”
BackgroundThe tyrosine phosphatase Shp2 (PTPN11) in cancer
Chan, G., Kalaitzidis, D., & Neel, B. G. (2008) · Cancer and Metastasis Reviews · doi:10.1007/s10555-008-9126-y · Cited by 382
“Similar effects have been observed utilizing cells from mice with loss of Nf1 [71–75] or expressing a gain-of-function KRas allele [76, 77].”
BackgroundA model for RAS mutation patterns in cancers: finding the sweet spot
Li, S., Balmain, A., & Counter, C. M. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0076-6 · Cited by 384
PTPN11 is the first identified proto-oncogene that encodes a tyrosine phosphatase
Chan, R. J., & Feng, G.-S. (2007) · Blood · doi:10.1182/blood-2006-07-028829 · Cited by 371
Developmental and species-divergent globin switching are driven by BCL11A
Sankaran, V. G., Xu, J., Ragoczy, T., Ippolito, G. C., Walkley, C. R., Maika, S. D., Fujiwara, Y., Ito, M., Groudine, M., Bender, M. A., et al. (2009) · Nature · doi:10.1038/nature08243 · Cited by 379
Niemeyer, C. M., Kang, M. W., Shin, D. H., Furlan, I., Erlacher, M., Bunin, N. J., Bunda, S., Finklestein, J. Z., Sakamoto, K. M., Gorr, T. A., et al. (2010) · Nature Genetics · doi:10.1038/ng.641 · Cited by 374
Self-citationOncogenic Ras in tumour progression and metastasis
Giehl, K. (2005) · Biological Chemistry · doi:10.1515/bc.2005.025 · Cited by 287
“over, targeted activation of latent oncogenic K-Ras in haematopoietic cells in an interferon-inducible transgenic mouse model resulted in fatal myeloproliferative disorders (Braun et al., 2004), thereby demonstrating that oncogenic K-Ras is sufficient to induce myeloid leukaemia in mice.”
BackgroundSallmyr, A., Fan, J., & Rassool, F. V. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.036 · Cited by 285
Daniluk, J., Liu, Y., Deng, D., Chu, J., Huang, H., Gaiser, S., Cruz-Monserrate, Z., Wang, H., Ji, B., & Logsdon, C. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci59743 · Cited by 276
“The observation that mutant Ras can be activated by stimuli has been previously reported (38) .”
Mohi, M. G., Williams, I. R., Dearolf, C. R., Chan, G., Kutok, J. L., Cohen, S., Morgan, K., Boulton, C., Shigematsu, H., Keilhack, H., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.01.010 · Cited by 277
The role of CREB as a proto-oncogene in hematopoiesis and in acute myeloid leukemia
Shankar, D. B., Cheng, J. C., Kinjo, K., Federman, N., Moore, T. B., Gill, A., Rao, N. P., Landaw, E. M., & Sakamoto, K. M. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.02.018 · Cited by 239
“Oncogenic K-ras expression in myeloid progenitor cells has been shown to result in myeloproliferative disease, but not AML (Braun et al., 2004; Chan et al., 2004).”
BackgroundKotecha, N., Flores, N. J., Irish, J. M., Simonds, E. F., Sakai, D. S., Archambeault, S., Diaz-Flores, E., Coram, M., Shannon, K. M., Nolan, G. P., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.08.014 · Cited by 233
“, 2007), the characteristic GM-CSF hypersensitivity of myeloid progenitors isolated from JMML patients in methylcellulose culture, and compelling data from Kras, Nf1, and Ptpn11 mutant mice linking genetic lesions found in JMML to MPD and GM-CSF hypersensitivity (Araki et al., 2004; Braun et al., 2004; Chan et al., 20…”
InfluentialSelf-citationProtein tyrosine phosphatase SHP-2: A proto-oncogene product that promotes Ras activation
Matozaki, T., Murata, Y., Saito, Y., Okazawa, H., & Ohnishi, H. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01257.x · Cited by 240
Gilad, O., Nabet, B. Y., Ragland, R. L., Schoppy, D. W., Smith, K. D., Durham, A. C., & Brown, E. J. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-2286 · Cited by 228
Targeting oncogenic Ras signaling in hematologic malignancies
Ward, A. F., Braun, B. S., & Shannon, K. M. (2012) · Blood · doi:10.1182/blood-2012-05-378596 · Cited by 209
Self-citationTissue-Specific Oncogenic Activity of KRASA146T
Poulin, E. J., Bera, A. K., Lu, J., Lin, Y.-J., Strasser, S. D., Paulo, J. A., Huang, T. Q., Morales, C., Yan, W., Cook, J., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1220 · Cited by 197
Self-citationLe, X., Langenau, D. M., Keefe, M. D., Kutok, J. L., Neuberg, D. S., & Zon, L. I. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611302104 · Cited by 184
ERKs in cancer: friends or foes?
Deschênes-Simard, X., Kottakis, F., Meloche, S., & Ferbeyre, G. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-2381 · Cited by 186
Mercer, K., Giblett, S., Green, S., Lloyd, D., DaRocha Dias, S., Plumb, M., Marais, R., & Pritchard, C. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-2211 · Cited by 179
“myeloproliferative disorders (13), and somatic activation of K-ras in mice using the Mx1-Cre strain induces a similar myeloproliferative disorder (37, 48), indicating that oncogenic B-RAF and RAS target different populations of Mx1-Cre–expressing cells.”
Defective erythroid differentiation in miR-451 mutant mice mediated by 14-3-3ζ
Patrick, D. M., Zhang, C. C., Tao, Y., Yao, H., Qi, X., Schwartz, R. J., Jun-Shen Huang, L., & Olson, E. N. (2010) · Genes & Development · doi:10.1101/gad.1942810 · Cited by 178
“Hyperactivation of these pathways blocks terminal erythroid differentiation and leads to cytokine-independent growth of erythroid progenitors (Braun et al. 2004).”
Backgroundp53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal
Zhao, Z., Zuber, J., Diaz-Flores, E., Lintault, L., Kogan, S. C., Shannon, K., & Lowe, S. W. (2010) · Genes & Development · doi:10.1101/gad.1940710 · Cited by 166
“Taken together, these in vitro results indicate that loss of p53 enhances proliferation of myeloid progenitor cells, and, in combination with oncogenic Kras, enables these cells to continually self-renew. p53 loss enables KrasG12D-expressing myeloid progenitors to become leukemia-initiating cells In contrast to KrasG1…”
BackgroundResultInfluentialSelf-citationNiemela, J. E., Lu, L., Fleisher, T. A., Davis, J., Caminha, I., Natter, M., Beer, L. A., Dowdell, K. C., Pittaluga, S., Raffeld, M., et al. (2011) · Blood · doi:10.1182/blood-2010-07-295501 · Cited by 170
Rassool, F. V., Gaymes, T. J., Omidvar, N., Brady, N., Beurlet, S., Pla, M., Reboul, M., Lea, N., Chomienne, C., Thomas, N. S. B., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-4807 · Cited by 172
“We wished to examine the effect that decreasing ROS activity would have on DNA damage and repair in MDS/MPDmice in vivo .”
BackgroundJuvenile myelomonocytic leukemia: who’s the driver at the wheel?
Niemeyer, C. M., & Flotho, C. (2019) · Blood · doi:10.1182/blood-2018-11-844688 · Cited by 169
Matsuda, K., Shimada, A., Yoshida, N., Ogawa, A., Watanabe, A., Yajima, S., Iizuka, S., Koike, K., Yanai, F., Kawasaki, K., et al. (2007) · Blood · doi:10.1182/blood-2006-09-046649 · Cited by 162
“Braun et al.(19) reported that somatic activation of a latent KRAS allele, the mutation identical to Case 6, rapidly induces a fatal myeloproliferative disorder in mice.”
BackgroundChildhood and Adolescent Lymphoid and Myeloid Leukemia
Pui, C.-H., Schrappe, M., Ribeiro, R. C., & Niemeyer, C. M. (2004) · Hematology · doi:10.1182/asheducation-2004.1.118 · Cited by 163
Recent advances in the pathogenesis and treatment of juvenile myelomonocytic leukaemia
Loh, M. L. (2011) · British Journal of Haematology · doi:10.1111/j.1365-2141.2010.08525.x · Cited by 160
“Animal models have subsequently revealed that Kras mutant mice also develop fatal myeloid disorders that resemble JMML in vivo and in vitro (Braun et al, 2004; Chan et al, 2004).”
BackgroundJuvenile myelomonocytic leukemia: A report from the 2nd International JMML Symposium
Chan, R. J., Cooper, T. M., Kratz, C. P., Weiss, B., & Loh, M. L. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.08.022 · Cited by 167
“Hematopoietic progenitors from Nf1−/− and KrasG12D mice demonstrate elevated Ras-GTP, hypersensitivity to GM-CSF, and produce MPD in vivo [38–40].”
BackgroundHematopoiesis and leukemogenesis in mice expressing oncogenic NrasG12D from the endogenous locus
Li, Q., Haigis, K. M., McDaniel, A., Harding-Theobald, E., Kogan, S. C., Akagi, K., Wong, J. C. Y., Braun, B. S., Wolff, L., Jacks, T., et al. (2011) · Blood · doi:10.1182/blood-2010-04-280750 · Cited by 154
Self-citationNiemeyer, C. M. (2014) · Haematologica · doi:10.3324/haematol.2014.114595 · Cited by 140
“Similarly, mice expressing oncogenic Kras in hematopoietic cells develop a fatal MPD with 100% penetrance that is characterized by leukocytosis, splenomegaly, and anemia, with death at approximately three months of age.(67,68) There is a puzzling interface between KRAS-associated lymphoproliferative disease (RALD) and…”
BackgroundNiemeyer, C. M., & Kratz, C. P. (2008) · British Journal of Haematology · doi:10.1111/j.1365-2141.2007.06958.x · Cited by 155
“It has recently been demonstrated that oncogenic RAS is sufficient to initiate a rapidly fatal myeloproliferative disorder in mice associated with hyperproliferation, tissue infiltration and aberrant responses to growth factors (Braun et al, 2004).”
BackgroundFunctional analysis of leukemia-associated PTPN11 mutations in primary hematopoietic cells
Schubbert, S., Lieuw, K., Rowe, S. L., Lee, C. M., Li, X., Loh, M. L., Clapp, D. W., & Shannon, K. M. (2005) · Blood · doi:10.1182/blood-2004-11-4207 · Cited by 148
Self-citationChen, X., Mitsutake, N., LaPerle, K., Akeno, N., Zanzonico, P., Longo, V. A., Mitsutake, S., Kimura, E. T., Geiger, H., Santos, E., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0900343106 · Cited by 141
“These data are consistent with the effects of endogenous expression of activated Kras in MEFs and in hematopoietic cells (7, 23).”
ResultCritical requirement for Stat5 in a mouse model of polycythemia vera
Yan, D., Hutchison, R. E., & Mohi, G. (2012) · Blood · doi:10.1182/blood-2011-03-345215 · Cited by 131
Huang, X.-F., Luo, S.-K., Xu, J., Li, J., Xu, D.-R., Wang, L., Yan, M., Wang, X.-R., Wan, X., Zheng, F.-M., et al. (2007) · Blood · doi:10.1182/blood-2007-07-099325 · Cited by 139
Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1genes
Gelsi-Boyer, V., Trouplin, V., Adélaïde, J., Aceto, N., Remy, V., Pinson, S., Houdayer, C., Arnoulet, C., Sainty, D., Bentires-Alj, M., et al. (2008) · BMC Cancer · doi:10.1186/1471-2407-8-299 · Cited by 126
“Germline RAS mutations induce precursor lesions and especially myeloproliferative disorders that resemble JMML and CMML [27-29].”
Mutation of Genes Affecting the RAS Pathway Is Common in Childhood Acute Lymphoblastic Leukemia
Case, M. C., Matheson, E. C., Minto, L., Hassan, R., Harrison, C. J., Bown, N. P., Bailey, S., Vormoor, J. H., Hall, A. G., & Irving, J. A. E. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0101 · Cited by 152
Li, L., Piloto, O., Nguyen, H. B., Greenberg, K., Takamiya, K., Racke, F., Huso, D., & Small, D. (2008) · Blood · doi:10.1182/blood-2007-08-109942 · Cited by 130
Oncogenic Nras has bimodal effects on stem cells that sustainably increase competitiveness
Li, Q., Bohin, N., Wen, T., Ng, V., Magee, J., Chen, S.-C., Shannon, K., & Morrison, S. J. (2013) · Nature · doi:10.1038/nature12830 · Cited by 126
Self-citationPlag1 and Plagl2 are oncogenes that induce acute myeloid leukemia in cooperation with Cbfb-MYH11
Landrette, S. F., Kuo, Y., Hensen, K., van Doorn-Khosrovani, S. B. V. W., Perrat, P. N., de Ven, W. J. M. V., Delwel, R., & Castilla, L. H. (2004) · Blood · doi:10.1182/blood-2004-09-3630 · Cited by 144
Mechanisms controlling pathogenesis and survival of leukemic stem cells
Jordan, C. T., & Guzmán, M. L. (2004) · Oncogene · doi:10.1038/sj.onc.1207935 · Cited by 154
“Similarly, recent studies have also employed conditional alleles of leukemic oncogenes in transgenic mice as a means to model early stages of myeloid leukemia (Braun et al., 2004; Chan et al., 2004).”
ResultJuvenile myelomonocytic leukemia and chronic myelomonocytic leukemia
Emanuel, P. D. (2008) · Leukemia · doi:10.1038/leu.2008.162 · Cited by 128
Dasgupta, B., Yi, Y., Hegedűs, B., Weber, J. D., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1842 · Cited by 130
Chan, G., Kalaitzidis, D., Usenko, T., Kutok, J. L., Yang, W., Mohi, M. G., & Neel, B. G. (2009) · Blood · doi:10.1182/blood-2008-10-182626 · Cited by 121
Mechanisms of Perineural Invasion
Bakst, R. L., & Wong, R. J. (2016) · Journal of Neurological Surgery Part B Skull Base · doi:10.1055/s-0036-1571835 · Cited by 134
Wang, J., Liu, Y., Li, Z., Du, J., Ryu, M., Taylor, P. R., Fleming, M. D., Young, K. H., Pitot, H. C., & Zhang, J. (2010) · Blood · doi:10.1182/blood-2010-04-281527 · Cited by 121
Herrera-Merchan, A., Arranz, L., Ligos, J., de Molina, A., Domínguez, O., & González, S. (2012) · Nature Communications · doi:10.1038/ncomms1623 · Cited by 141
RetractedLoh, M. L., Reynolds, M. G., Vattikuti, S., Gerbing, R. B., Alonzo, T. A., Carlson, E. J., Cheng, J. W., Lee, C. M., Lange, B. J., & Meshinchi, S. (2004) · Leukemia · doi:10.1038/sj.leu.2403492 · Cited by 121
Sjogren, A.-K. M., Andersson, K. M. E., Liu, M., Cutts, B. A., Karlsson, C., Wahlstrom, A. M., Dalin, M., Weinbaum, C., Casey, P. J., Tarkowski, A., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30868 · Cited by 117
“In the future, it would be interesting to define the impact of GGTase-I deficiency on other experimental myeloproliferative disease syndromes, for example the one elicited when the KLSL allele is activated by the Mx1-Cre transgene (40, 41).”
BackgroundChang, T. Y., Dvorak, C. C., & Loh, M. L. (2014) · Blood · doi:10.1182/blood-2014-03-300319 · Cited by 121
“Animal models have subsequently revealed that Kras mutant mice also develop fatal myeloid disorders that resemble JMML in vivo and in vitro.(45,46) Doisaki et al(47) recently reported 2 patients with non-syndromic JMML who were found to have somatic mosaicism for oncogenic NRAS G12D and G12S mutations, with mutated al…”
BackgroundVan Meter, M. E. M., Díaz-Flores, E., Archard, J. A., Passegué, E., Irish, J. M., Kotecha, N., Nolan, G. P., Shannon, K., & Braun, B. S. (2007) · Blood · doi:10.1182/blood-2006-09-047530 · Cited by 114
Self-citationAberrant cytokine signaling in leukemia
Etten, R. A. V. (2007) · Oncogene · doi:10.1038/sj.onc.1210758 · Cited by 121
“P A A uthor M anuscript Table 1 Dysregulated TKs in leukemia Kinase Activating mechanism(s) Leukemia Kinase inhibitor(s) ABL Fusion to BCR Fusion to TEL Fusion to NUP214 or EML1 CML AML, ALL, atypical CML T-ALL Imatinib Dasatinib Nilotinib ALK Fusion to NPM Anaplastic large cell lymphoma (None available) ARG Fusion to…”
BackgroundInfluentialHerrera-Merchan, A., Arranz, L., Ligos, J. M., de Molina, A., Dominguez, O., & Gonzalez, S. (2017) · Nature Communications · doi:10.1038/ncomms14005 · Cited by 108
Role of Ras/Raf/MEK/ERK signaling in physiological hematopoiesis and leukemia development
Chung, E., & Kondo, M. (2010) · Immunologic Research · doi:10.1007/s12026-010-8187-5 · Cited by 114
Dido gene expression alterations are implicated in the induction of hematological myeloid neoplasms
Fütterer, A., Campanero, M. R., Leonardo, E., Criado, L. M., Flores, J. M., Hernández‐Rivas, J. M., Miguel, J. F. S., & Martínez‐A, C. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24177 · Cited by 106
Zhang, J., Wang, J., Liu, Y., Sidik, H., Young, K. H., Lodish, H. F., & Fleming, M. D. (2009) · Blood · doi:10.1182/blood-2008-01-134262 · Cited by 102
Wang, J., Liu, Y., Li, Z., Wang, Z., Tan, L. X., Ryu, M.-J., Meline, B., Du, J., Young, K. H., Ranheim, E., et al. (2011) · Blood · doi:10.1182/blood-2010-12-326058 · Cited by 98
Oncogenic Kras Initiates Leukemia in Hematopoietic Stem Cells
Sabnis, A. J., Cheung, L. S., Dail, M., Kang, H. C., Santaguida, M. A., Hermiston, M. L., Passegue, E. A., Shannon, K., & Braun, B. S. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000059 · Cited by 106
“As described [13], 21-d-old Mx1-Cre, Kras were injected IP with 250 lg pIpC (Sigma).”
BackgroundMethodSelf-citationGlioma Formation in Neurofibromatosis 1 Reflects Preferential Activation of K-RAS in Astrocytes
Dasgupta, B., Li, W., Perry, A., & Gutmann, D. H. (2005) · Cancer Research · doi:10.1158/0008-5472.236.65.1 · Cited by 114
From top to bottom: midkine and pleiotrophin as emerging players in immune regulation
Sorrelle, N. B., Dominguez, A. T. A., & Brekken, R. A. (2017) · Journal of Leukocyte Biology · doi:10.1189/jlb.3mr1116-475r · Cited by 112
“of PTN in that context is undetermined [136, 137].”
BackgroundKindler, T., Cornejo, M. G., Scholl, C., Liu, J., Leeman, D. S., Haydu, J. E., Fröhling, S., Lee, B. H., & Gilliland, D. G. (2008) · Blood · doi:10.1182/blood-2008-03-147587 · Cited by 95
K-Ras V14I recapitulates Noonan syndrome in mice
Hernández-Porras, I., Fabbiano, S., Schuhmacher, A. J., Aicher, A., Cañamero, M., Cámara, J. A., Cussó, L., Desco, M., Heeschen, C., Mulero, F., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1418126111 · Cited by 96
Inherited predispositions and hyperactive Ras in myeloid leukemogenesis
Lauchle, J. O., Braun, B. S., Loh, M. L., & Shannon, K. (2006) · Pediatric Blood & Cancer · doi:10.1002/pbc.20644 · Cited by 94
“Interestingly, cells expressing E76K or D61Y SHP-2 proliferated extensively under these conditions, which is also characteristic of Kras mutant cells [52].”
BackgroundSelf-citationFocus on myeloproliferative diseases and myelodysplastic syndromes
Etten, R. A. V., & Shannon, K. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.12.004 · Cited by 93
“This is supported by studies of Nf1, Kras, and Ptpn11 mutant mice, all of which develop myeloid disorders resembling JMML and CMML (Araki et al., 2004; Braun et al., 2004; Chan et al., 2004; Le et al., 2004).”
ResultSelf-citationOncogenic NRAS rapidly and efficiently induces CMML- and AML-like diseases in mice
Parikh, C., Subrahmanyam, R., & Ren, R. (2006) · Blood · doi:10.1182/blood-2004-08-009498 · Cited by 104
Inactivating Icmt ameliorates K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Liu, M., Lindskog, A., Karlsson, C., Sjogren, A.-K. M., Andersson, K. M. E., Young, S. G., & Bergo, M. O. (2008) · Blood · doi:10.1182/blood-2007-06-094060 · Cited by 91
A MEK Inhibitor Abrogates Myeloproliferative Disease in Kras Mutant Mice
Lyubynska, N., Gorman, M. F., Lauchle, J., Hong, W. X., Akutagawa, J., Shannon, K., & Braun, B. S. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001069 · Cited by 92
Self-citationNeuronal NF1/RAS regulation of cyclic AMP requires atypical PKC activation
Anastasaki, C., & Gutmann, D. H. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu389 · Cited by 95
“S1B–D), we focused on genetically engineered mouse strains in which one allele of the Nras (LSL-Nras) or Kras (LSL-Kras) genes were inactivated (23,24).”
Oncogenic NRAS, KRAS, and HRAS Exhibit Different Leukemogenic Potentials in Mice
Parikh, C., Subrahmanyam, R., & Ren, R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0778 · Cited by 79
Melo-Cardenas, J., Xu, Y., Wei, J., Tan, C., Kong, S., Gao, B., Montauti, E., Kirsammer, G., Licht, J. D., Yu, J., et al. (2018) · Blood · doi:10.1182/blood-2017-10-811760 · Cited by 84
Xu, J., Hedberg, C., Dekker, F. J., Li, Q., Haigis, K. M., Hwang, E., Waldmann, H., & Shannon, K. (2012) · Blood · doi:10.1182/blood-2011-06-358960 · Cited by 80
Self-citationThe duality of human oncoproteins: drivers of cancer and congenital disorders
Castel, P., Rauen, K. A., & McCormick, F. P. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0256-z · Cited by 83
Rowland, S. L., DePersis, C. L., Torres, R. M., & Pelanda, R. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20091673 · Cited by 74
“Chimeric mice were analyzed at 3 wk after transfer to limit tumor development caused by the expression of the constitutively active Ras oncogene (Braun et al., 2004; Chan et al., 2004).”
BackgroundGfi1 integrates progenitor versus granulocytic transcriptional programming
Horman, S. R., Velu, C. S., Chaubey, A., Bourdeau, T., Zhu, J., Paul, W. E., Gebelein, B., & Grimes, H. L. (2009) · Blood · doi:10.1182/blood-2008-09-179747 · Cited by 74
Targeting Ras in myeloid leukemias
Braun, B. S., & Shannon, K. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1005 · Cited by 74
Self-citationRce1 deficiency accelerates the development of K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Karlsson, C., Andersson, K. M. E., Liu, M., Sjogren, A.-K. M., Swolin, B., Young, S. G., & Bergo, M. O. (2007) · Blood · doi:10.1182/blood-2006-05-024752 · Cited by 72
Structure, Function, and Pathogenesis of SHP2 in Developmental Disorders and Tumorigenesis
Huang, W.-Q., Lin, Q., Zhuang, X., Cai, L.-L., Ruan, R.-S., Lu, Z.-X., & Tzeng, C.-M. (2014) · Current Cancer Drug Targets · doi:10.2174/1568009614666140717105001 · Cited by 69
Xu, D., Wang, S., Yu, W., Chan, G., Araki, T., Bunting, K. D., Neel, B. G., & Qu, C. (2010) · Blood · doi:10.1182/blood-2010-01-265652 · Cited by 75
Yan, L., Findlay, G. M., Jones, R., Procter, J., Cao, Y., & Lamb, R. F. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600028200 · Cited by 67
Niimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69
Mll5 contributes to hematopoietic stem cell fitness and homeostasis
Zhang, Y., Wong, J., Klinger, M., Tran, M. T., Shannon, K. M., & Killeen, N. (2009) · Blood · doi:10.1182/blood-2008-05-159905 · Cited by 68
Self-citationOmidvar, N., Kogan, S. C., Beurlet, S., Pogam, C. L., Janin, A., West, R., Noguera, M., Reboul, M., Soulié, A., Lebœuf, C., et al. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0196 · Cited by 68
“( 34 , 43). The last two models are particularly elegant in that despite the physiologic levels of mutant KRAS driven by its own promoter, alone a lethal disease ensues rapidly due to the Mx1 targeting a different progenitor to the MRP8-driven NRASD12 used in our present study.”
BackgroundMethodSelf-citationIdentification of mutant K-Ras-dependent phenotypes using a panel of isogenic cell lines
Vartanian, S., Bentley, C., Brauer, M. J., Li, L., Shirasawa, S., Sasazuki, T., Kim, J.-S., Haverty, P., Stawiski, E., Modrusan, Z., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.394130 · Cited by 65
“K-ras G13D 15 Het (14), Hom (1) Lung (4), breast (1), colon (6), blood (1), ileum (1), lymph node (2) 0.”
Dail, M., Li, Q., McDaniel, A., Wong, J., Akagi, K., Huang, B., Kang, H. C., Kogan, S. C., Shokat, K., Wolff, L., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1001064107 · Cited by 63
“Using the IFN-regulated Mx1-Cre transgene to activate a conditional mutant Kras LSL-G12D allele in hematopoietic cells causes an aggressive myeloproliferative disease (MPD) (23, 24).”
InfluentialSelf-citationOncogenic K-ras cooperates with PML-RAR to induce an acute promyelocytic leukemia-like disease
Chan, I. T., Kutok, J. L., Williams, I. R., Cohen, S., Moore, S., Shigematsu, H., Ley, T. J., Akashi, K., Beau, M. M. L., & Gilliland, D. G. (2006) · Blood · doi:10.1182/blood-2006-04-015040 · Cited by 67
Hoshii, T., Kasada, A., Hatakeyama, T., Ohtani, M., Tadokoro, Y., Naka, K., Ikenoue, T., Ikawa, T., Kawamoto, H., Fehling, H. J., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1320265111 · Cited by 66
Xiao, W., Ando, T., Wang, H., Kawakami, Y., & Kawakami, T. (2010) · Blood · doi:10.1182/blood-2010-05-283937 · Cited by 70
Zhang, J., & Lodish, H. F. (2004) · Blood · doi:10.1182/blood-2004-04-1362 · Cited by 62
Molecular pathogenesis of atypical CML, CMML and MDS/MPN-unclassifiable
Zoi, K., & Cross, N. C. P. (2014) · International Journal of Hematology · doi:10.1007/s12185-014-1670-3 · Cited by 67
“The most frequent mutations in KRAS and NRAS genes occur at codons 12, 31 and 61 [29–31].”
BackgroundLoh, M. L., & Mullighan, C. G. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1936 · Cited by 65
“develop fatal myeloid disorders that resemble JMML in vivo and in vitro (67, 68).”
BackgroundLi, K., Zhang, Y., Liu, X., Liu, Y., Gu, Z., Cao, H., Dickerson, K. E., Chen, M., Chen, W., Shao, Z., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1128 · Cited by 80
Wiemels, J. L., Zhang, Y., Chang, J. S.-M., Zheng, S., Metayer, C., Zhang, L., Smith, M. T., Ma, X., Selvin, S., Buffler, P. A., et al. (2005) · Leukemia · doi:10.1038/sj.leu.2403641 · Cited by 61
K-ras/PI3K-Akt Signaling Is Essential for Zebrafish Hematopoiesis and Angiogenesis
Liu, L., Zhu, S., Gong, Z., & Low, B. C. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002850 · Cited by 60
“Moreover, oncogenic RAS were known to associate with blood cancer and other blood disorders [20–22].”
BackgroundModelling oncogenic Ras/Raf signalling in the mouse
Karreth, F. A., & Tuveson, D. A. (2009) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.12.006 · Cited by 59
Self-citation
Metadata
- Authors
- Braun, B. S., Tuveson, D. A., Kong, N., Le, D. T., Kogan, S. C., Rozmus, J., Le Beau, M. M., Jacks, T. E., & Shannon, K. M.
- Affiliations
- University of California, San Francisco (US)
- University of California, Los Angeles (US)
- Departments of Pediatrics and Laboratory Medicine and Comprehensive Cancer Center, University of California, San Francisco, CA 94143; Abramson Center for Cancer Research, University of Pennsylvania, Philadelphia, PA 19104; Section of Hematology/Oncology, Department of Medicine and Cancer Research Center, University of Chicago, Chicago, IL 60637; and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139
- Corresponding author
- Shannon, Kevin M.
- ORCID
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2003-12-29
- Volume
- 101
- Issue
- 2
- Pages
- 597-602
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC327193
- OpenAlex
- W2017349699
- Cited by
- 299
- References
- 53
- Citations by year
- 2026: 1 · 2025: 7 · 2024: 10 · 2023: 3 · 2022: 5 · 2021: 12 · 2020: 7 · 2019: 12 · 2018: 9 · 2017: 8 · 2016: 13 · 2015: 8 · 2014: 24 · 2013: 16 · 2012: 17
- FWCI
- 7.63
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Frank A. Campini Foundation
- National Institutes of Health
- National Cancer Institute (CA 84221, R01CA072614, U01CA084221, U01CA084306, R37CA072614, CA84306, CA72614)
- National Institute of Diabetes and Digestive and Kidney Diseases (T32DK007636, T32 DK-07636)
- Topics
- Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Keywords
- oncogenic KRAS, KRAS G12D, RAS mutations, myeloproliferative neoplasms, myeloid leukemia, hematopoietic cells, Ras-GTP, hyperproliferation, leukemogenesis, mouse model
- MeSH terms
- Animals, Bone Marrow Cells, Flow Cytometry, Karyotyping, Myeloproliferative Disorders, Genes, ras, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.